TheN-methyl-D-aspartate receptor (NMDAR), a pivotal entity for synaptic plasticity and excitotoxicity in the brain, is a target ofpsychotomimetic drugs such as phencyclidine (PCP) and dizolcipine . In contrast, a related glutamate receptor, the a-anuno-3-hydroxy- (1, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Their potency as NMDAR blockers has made this class of agents a promising strategy to prevent glutamate-mediated neuronal cell death and associated disorders such as stroke, epilepsy, and Huntington disease (2-6). Although a wealth of information on the molecular mechanism of NMDAR blockade by PCP and MK-801 has accrued (1, 9-21), the structural determinants that specify the receptor affinity are still elusive. Here we report the molecular design of PCP and MK-801 high-affinity binding sites on a cloned human brain non-NMDAR, GluRl, one of the a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate (KA) The supernatants were subjected to SDS/PAGE (27) using 7.5% mini Protean gels (Bio-Rad). Proteins were electrotransferred onto poly(vinylidene difluoride) membranes (Bio-Rad).
drugs. Three point mutations on GluRl, mimicking homologous residues on the NMDAR, confer the PCP and MK-801 blockade properties that are characteristic of the NMDAR-namely, high potency, voltage dependence, and use dependence. The molecular determinants that specify the PCP block appear confined to the putative M2 transmembrane segment, whereas the sensitivity to MK-801 requires an interplay between residues from M2 and M3. Given the plausible involvement of the NMDAR in the etiology of several neurodegenerative diseases and in excitotoxic neuronal cell death, tailored glutamate receptors with specific properties may be models for designing and screening new drugs targeted to prevent glutamate-mediated neural damage.
Ionotropic glutamate receptors (GluRs) play a fundamental role in the function (1) and dysfunction (2-6) of the brain. These receptors are classified in two major classes according to their physiological and pharmacological properties: the N-methyl-D-aspartate receptor (NMDAR) and non-NMDAR (1, 7, 8) . NMDARs are highly permeable to calcium and are considered crucial for induction of synaptic plasticity and neurotoxicity (1) (2) (3) (4) (5) (6) (7) (8) . NMDARs, in contrast to non-NMDARs, are targets of potent psychotropic agents such as the dissociative anesthetic phencyclidine (PCP) and the anticonvulsant and anxiolytic dizolcipine (MK-801), collectively known as noncompetitive NMDA antagonists (1, (7) (8) (9) (10) (11) (12) (13) (14) . PCP and MK-801, open channel blockers of the NMDAR that transiently occlude the pore, act with nanomolar inhibition constants and in a voltage-and use-dependent manner (1, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Their potency as NMDAR blockers has made this class of agents a promising strategy to prevent glutamate-mediated neuronal cell death and associated disorders such as stroke, epilepsy, and Huntington disease (2) (3) (4) (5) (6) .
Although a wealth of information on the molecular mechanism of NMDAR blockade by PCP and MK-801 has accrued (1, 9-21), the structural determinants that specify the receptor affinity are still elusive. Here we report the molecular design of PCP and MK-801 high-affinity binding sites on a cloned human brain non-NMDAR, GluRl, one of the a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate (KA) receptors that is weakly sensitive to these drugs (22 (23) . Sitedirected mutagenesis was performed on single-stranded DNA (25) or by a combination of polymerase chain reaction (PCR) and subcloning. For the latter, the mutagenic primer was one of a pair of PCR primers used to amplify a fragment of the GluRl cDNA, which was then subcloned back into the GluRl cDNA. Mutants were screened and confirmed by dideoxy sequencing (22, 23) . cRNA was synthesized from linearized cDNA using the mMessage mMachine kit from Ambion.
Electrophysiological ponent of the ionic pore of the neurotransmitter-gated channel superfamily (7, 8, 19, 20, (28) (29) (30) (31) (32) (Fig. 1) . As a first approach, we designed chimeric GluRls containing either the entire M2 segment of the NMDAR from human brain (NMDAR1) (23) (chimera A, residues 582-603), its C-terminal half (chimera B, residues 593-602), or its C-terminal third (chimera C, residues 596-602). These chimeric receptors did not express functional ion channels in Xenopus oocytes (Table 1 ).
An alternative strategy involved the stepwise replacement of specific residues of GluRl to mimic NMDAR1 (Fig. 1) . Mutation of asparagine at position 598 on the NMDAR to the glutamine found in GluRl decreased its sensitivity to PCP and MK-801 (19, 20) , suggesting that this residue is a key component of the PCP binding site of NMDARs. It is conceivable that mutation of the corresponding glutamine at position 582 on the GluRl to asparagine would increase its sensitivity to both channel blockers. As predicted, the Q582N mutant ( Fig.  2A To identify these molecular determinants, we mutated adjacent residues upstream and downstream of Q582 ( Fig. 1 ). Introduction of a tryptophan at position 577 (L577W), a residue absolutely conserved in all NMDAR subunits (7, 8, 33, 34) , conferred to GluRl a modest increase in blockade efficacy-i.e., 2-fold for PCP and 4-fold for MK-801 (Table 1) . In contrast, no enhanced sensitivity to PCP or MK-801 was effected by insertion of isoleucine and glycine at position 585, n/N, number of oocytes (n) that expressed KA-evoked currents out of the total number of oocytes tested (N); NB, no detectable blockade of the KA response. Potency was calculated as the ratio of the IC5o of GluRl to that of the mutant receptor. Chimeras A, B, and C denote chimeric GluRls containing the entire M2 transmembrane segment of the NMDAR1 (23) (residues 582-603), the C-terminal half (residues 593-602), and the C-terminal third (residues 596-602) (Fig. 1) . Mutant receptors exhibited an efficacy constant for activation by KA of 30-40 ,uM, similar to that of GluRi (22) . Ionic currents elicited by 500 F&M KA at -120 mV for GluRl and its mutants were as follows:'200-2000 nA for GluRl, G568T, A579V, F580L, M581L, and L577W/Q582N; 500-8000 nA for L577W and L577W/Q582T; 100-1000 nA for M581L/Q582N; 10-200 nA for Q582N, C585IG, W602A, S610A, T605A/S610A, L577W/A579V/Q582N, L577W/Q582N/S610A, and L577W/Q582T/S610A. Dashes indicate mutants that failed to express KA-activated currents; however, receptor protein was expressed in oocytes as evidenced by immunoblots using an anti-GluRl antibody. Mutants in boldface type are those that displayed the highest sensitivity to the blockers. *Mean ± SEM. (Fig. 1, Table 1 ). Mutant Q583S failed to express KA-activated currents (Table 1) . Therefore, a tryptophan at position 577 on GluRl may contribute to drug binding.
We hypothesized that a double mutant receptor incorporating these two NMDAR determinants, W577 and N582 (L577W/Q582N), would display a higher affinity to PCP and MK-801 than that exhibited by either of the single mutants, L577W or Q582N. In fact, the L577W/Q582N double mutant (Fig. 24 Lower Left) displayed 10-fold higher affinity for PCP than the Q582N single mutant and 100-fold higher sensitivity than GluRl (Fig. 2C, Table 1) . Surprisingly, however, the L577W/Q582N double mutant expressed the same sensitivity to MK-801 as the Q582N mutant (Table 1) . These results suggest that a tryptophan at position 577 is important for binding PCP but not MK-801.
To substantiate this finding, we mutated the equivalent residues at these two positions on M2 of NMDAR1 to the corresponding amino acids on GluRl (Fig. 1) . Predictably, the opposite phenotype was produced (Fig. 3) : mutation of asparagine at position 598 to glutamine decreased the blockade potency of PCP by '300-fold and of MK-801 by '800-fold. Additional mutation of tryptophan at position 593 to leucine (W593L/N598Q) further reduced the sensitivity to PCP (Fig.  3A) without altering that of MK-801 (Fig. 3B) . These results indicate that tryptophan at position 593 is a specific structural determinant of the PCP binding pocket on NMDARs. Thus, mutations of NMDAR1 and GluRl that permute the occurrence of tryptophan or asparagine at two key positions predictably switch the properties of the mutant channels. The reciprocity of the mutational strategy-namely, "gain-offunction" on GluRl (Fig. 2) and "loss-of-function" in NMDAR1 (Fig. 3) -asserts the reliability of these findings. Collectively, these results imply that the PCP and MK-801 binding pockets are specified by the contribution of different molecular determinants.
The Binding Site for MK-801 Requires an Interplay of Residues from M2 and M3 Segments. Since amino acid residues adjacent to glutamine at position 582 did not contribute to MK-801 sensitivity (Table 1) , we explored the Proc. Natl. Acad. Sci. USA 92 (1995) and MK-801, as compared with the asparagine-containing L577W/Q582N double mutant (Fig. 2C, Table 1 ). This enhancement may arise from the increased hydrogen bonding energy between the -OH group on threonine at position 582 and the -NH group on PCP or MK-801, as inferred from model PCP-like compounds (35) (36) (37) . As anticipated, introduction of the S610A mutation on M3 into the threonine-containing L577W/Q582T double mutant augmented the potency of the MK-801 blockade (Fig. 2BLowerRight andD) . The increment in affinity to PCP and MK-801 exhibited by the L577W/ Q582T/S610A triple mutant over that of GluRl amounts to -300-fold and 2000-fold, respectively (Table 1) potential involvemnent of residues from other transmembrane segments in structuring the MK-801 binding site. Segments Ml and M4 are poorly conserved among NMDARs (7, 8, 33, 34) and, presumably, not implicated in blockade by MK-801. In contrast, M3 is the most conserved segment of the four (7, 8, 33, 34) . In a highly similar region, residues W602, T605, and S610 of GluRl (Fig. 1) are alanine at the corresponding position of all NMDAR subunits cloned thus far (7, 8) . Strikingly, replacement of serine at position 610 on GluRl with alanine increased the potency of MK-801 blockade by 7-fold without affecting the IC50 of PCP (Table 1) , whereas the double mutant T605A/S610A did not further improve the MK-801 blockade (Table 1 ). This suggests the involvement of an alanine at position 610 in specifying the MK-801 binding site. We wondered if a triple mutant receptor incorporating a tryptophan at position 577, an asparagine at 582, and an alanine at 610 (L577W/Q582N/S610A) would acquire high sensitivity to PCP and MK-801. Indeed, the L577W/Q582N/ S610A triple mutant (Fig. 2B Lower Left) exhibited high affinity for both drugs, amounting to a 180-and 800-fold increase in sensitivity to PCP and MK-801 with respect to GluRl ( Table 1 ). The IC50 for both drugs exhibited by the triple mutant approaches, yet does not match, that of the NMDAR. Notwithstanding, the structural determinants that specify the PCP blockade appear confined to the M2 transmembrane segment, whereas an interplay of residues from M2 and M3 is involved in the design of the MK-801 binding pocket.
Hydrogen Bonding Plays a Fundamental Role on DrugReceptor Interactions. A common structural determinant for the sensitivity to both channel blockers is asparagine at position 582 of M2; this polar residue may form hydrogen bonds with the blockers (35) (36) (37) . To refine the design, we assessed the effect of replacing glutamine at 582 on GluRl by threonine. The rationale considered the introduction of a hydroxyl group at position 582, while maintaining a spatial volume similar to that of asparagine (T -93 A3 and N 96 A3). Unexpectedly, the Q582T mutant did not express measurable KA-activated inward currents ( Table 1 ). The double mutant at the two key positions on M2 L577W/Q582T, however, produced large KA-evoked ionic currents (Fig. 2A4 Lower Right) and a 2-fold increase in efficacy of block by PCP (22, 23, 26 (1, (15) (16) (17) (18) 21) . Fig. 4,4 shows that PCP and MK-801 blocked the mutant channels in a voltage-dependent manner, inhibiting at negative membrane potentials but not at depolarizing potentials. Fig. 4B demonstrates that repetitive pulses of KA, supplemented with 1 ,uM or 10 p,M blocker, progressively augmented the block of the KA-evoked ionic current of the L577W/Q582T mutant (-). Such blockade was exclusively observed when the blocker was simultaneously applied with KA (see also Fig. 2A and B Lower) . Recovery of the KA-elicited current after removal of the channel blockers from the agonistcontaining solution was also prolonged. The extent and the rate of recovery increased with more depolarizing voltages. This pattern of use dependence reflects the slow dissociation of the drug from its engineered binding site, as reported for the NMDAR (21) . The nature of the residue at position 582 appears crucial to endow the mutant receptors with usedependent blockade. Asparagine mutants do not display usedependent blockade by either drug (Fig. 4B, o, v) , consistent with the higher IC5o of these mutant receptors for the channel blockers (Table 1 ). In contrast, the efficacy and use dependency of block of the threonine mutants was more powerful: the L577W/Q582T/S610A mutant shows use-dependent blockade by PCP to the same extent as the L577W/Q582T mutant (data not shown) and, in addition, displays remarkable use-dependent blockade by MK-801 (Fig. 4B, v) . Further, block was effectively irreversible at hyperpolarized potentials, a distinctive property of these drugs at the NMDAR (21). Thus, just three point mutations on GluRl, L577W/Q582T/ S610A, created a receptor channel that exhibits the highpotency, voltage-dependent, and use-dependent blockade properties by PCP and MK-801 that are characteristic of the NMDAR.
Designing and restructuring a putative receptor site have taken us from a GluR that is weakly sensitive to PCP and MK-801 to a receptor that is blocked by both drugs with submicromolar inhibition constants, emulating the features that are characteristic of the NMDAR. The newly acquired sensitivity to PCP and MK-801 suggests that the triple mutant may structurally mimic the pore-lining and the drug-binding pocket of the NMDAR. Taken together, these results strengthen the notion that the M2 segment is an essential structural component of the ionic pore in the GluR superfamily and indicate a role of M3 in modulating aspects of pore function. Having identified key structural determinants in the channel lining of GluRs that interact with noncompetitive antagonists may facilitate molecular modeling studies of the pore-forming structure and the binding sites for blockers. Specifically, the implication of residues from M3 in the action of open channel blockers may require revision of the prevailing models of the receptor pore-lining structure based exclusively on M2 (28) (29) (30) (31) (32) and of the overall folding topology of the GluR superfamily (38) (39) (40) .
